Idexx Laboratories (IDXX) Non-Current Deffered Revenue (2009 - 2026)

Idexx Laboratories' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $32.3 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 20.49% year-over-year to $32.3 million; the TTM figure through Mar 2026 stood at $32.3 million (up 20.49% YoY), while the FY2025 annual figure was $32.2 million, up 19.44% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $32.3 million, roughly flat from $32.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $39.2 million in Q1 2022, with the low at $26.8 million in Q3 2024.
• The 5-year median for Non-Current Deffered Revenue is $30.4 million (2023), against an average of $30.6 million.
• The sharpest annual moves came in 2022 and 2026: Non-Current Deffered Revenue decreased 25.04% in 2022, then rose 20.49% in 2026.
• Idexx Laboratories' Non-Current Deffered Revenue stood at $30.9 million in 2022, then dropped by 7.55% to $28.5 million in 2023, then declined by 5.59% to $26.9 million in 2024, then climbed by 19.44% to $32.2 million in 2025, then advanced by 0.42% to $32.3 million in 2026.
• Business Quant data shows IDXX's Non-Current Deffered Revenue at $32.3 million in Q1 2026, $32.2 million in Q4 2025, and $31.1 million in Q3 2025.